SAN DIEGO, February 26, 2025 – Capstan Therapeutics, Inc. (“Capstan”),a biotechnology company dedicated to advancing in vivo reprogramming of cells through mRNA delivery using targeted lipid nanoparticles (tLNP), today announced that Capstan management will participate in 1x1 investor meetings at the following upcoming conferences.

TD Cowen 45th Annual Health Care Conference

Date: Monday, March 3 – Wednesday, March 5
Location: Boston Marriott Copley Place, Boston, MA

Leerink Partners Global Healthcare Conference 2025

Date: Sunday, March 9 – Wednesday, March 12
Location: W South Beach, Miami, FL

About Capstan Therapeutic, Inc. (www.capstantx.com)

Capstan is a biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. Our proprietary CellSeeker™ tLNP platform technology leverages novel lipid nanoparticles (LNPs) conjugated with recombinant protein binders, such as monoclonal antibodies. tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. Capstan’s CellSeeker™ technology has the potential to generate transformative therapies across a range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders.

For more information, please visit www.capstantx.com and follow us on LinkedIn.

Investors:
Miguel Arcinas
Senior Vice President of Corporate Development
Capstan Therapeutics
marcinas@capstantx.com

Media:
Rhiannon Jeselonis
Ten Bridge Communications
rhiannon@tenbridgecommunications.com